Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Level Biotechnology Inc. (3118:TWSE), powered by AI.
Level Biotechnology Inc. is currently trading at $31.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Level Biotechnology Inc. on Alpha Lenz.
View Level Biotechnology Inc.'s valuation metrics on Alpha Lenz.
“Level Biotechnology Inc.'s ROE is 14.0%. Explore profitability and growth together.”
Ask for details →Level Biotechnology Inc. is a biotechnology company specializing in the marketing and distribution of cell culture, immunology, and molecular biology products, as well as biomedical precision equipment. Founded in 1989 and headquartered in New Taipei City, Taiwan, the company serves a wide range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries. Notably, Level Biotechnology provides comprehensive preclinical contract research organization (CRO) services, including genetic toxicology, mammalian toxicology, pharmacology, biocompatibility, and model animal production. With over nine thousand square yards of laboratory space and internationally accredited animal facilities, the company adheres to rigorous standards such as Good Laboratory Practice (GLP) and ISO 17025. This combination of product distribution and high-quality testing services positions Level Biotechnology Inc. as a significant player supporting biomedical research, product development, and regulatory compliance in Taiwan’s healthcare and life sciences sectors.
“Level Biotechnology Inc.'s ROE is 14.0%. Explore profitability and growth together.”
Ask for details →Level Biotechnology Inc. (ticker: 3118) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 132 employees.
The current price is 31.25 with a P/E ratio of -x and P/B of -x.
ROE is 13.98% and operating margin is 11.34%. Annual revenue is $737M.